STOCK TITAN

Oncocyte Corporation - OCX STOCK NEWS

Welcome to our dedicated news page for Oncocyte Corporation (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncocyte Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncocyte Corporation's position in the market.

Rhea-AI Summary
Oncocyte Corporation receives positive coverage decision for VitaGraft Kidney diagnostic test, expects initial revenue in Q1 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
conferences
-
Rhea-AI Summary
Oncocyte Corporation (NASDAQ:OCX) will release its second quarter 2023 financial results on August 10, 2023. The company will host a conference call and webcast to discuss its financial results and recent highlights. Interested parties can access the live call via telephone or the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
Rhea-AI Summary
Oncocyte Corporation has published new data demonstrating the effectiveness of its VitaGraft Kidney test in distinguishing between antibody-mediated rejection (ABMR) and recurrent IgA nephropathy (IgAN) in kidney transplant patients. The test showed higher sensitivity and specificity for detecting ABMR compared to routine tests. This could help physicians select appropriate treatment more quickly and avoid unnecessary procedures. The company has also submitted its dd-cfDNA tests for Medicare reimbursement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
none
Rhea-AI Summary
Oncocyte Corporation (OCX) announces a 1-for-20 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The split will reduce outstanding shares to approximately 8,241,054 and will be effective on July 24, 2023. Shareholders will receive cash in lieu of fractional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.63%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
conferences
Rhea-AI Summary
Oncocyte Corporation reported financial results for Q1 2023, including a capital raise of $13.86 million and progress in developing kitted versions of their diagnostic tests. Consolidated revenues decreased by 50% compared to Q1 2022. R&D expenses decreased by $2.3 million, and G&A expenses decreased by $2.0 million. Sales and Marketing expenses decreased by $2.0 million due to the sale of Razor Genomics. A conference call to discuss the results will be held on May 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
Oncocyte Corporation

Nasdaq:OCX

OCX Rankings

OCX Stock Data

22.39M
3.73M
5.7%
55.18%
2.17%
In-Vitro Diagnostic Substance Manufacturing
Manufacturing
Link
US
Irvine

About OCX

oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.